10089996GenaClosedInvestment AcceleratorInnovate UKGena's mission is to provide critical genomic sequencing services to rare cancer patients. Gena offers a patient-centric approach to cancer genomic sequencing, helping put their genomic data in their own hands to make better and faster decisions with the aim of increasing their level of understanding of their diagnosis to provide greater insights to inform clinical decision-making. With our Whole Genome Sequencing service, Gena enables patients to uncover potential targeted and tailored treatment pathways, granting them and their clinicians a deeper understanding of their disease pathology. This service is invaluable for patients, who often have limited information about the underlying drivers of their cancer and few treatment options available. We then tap into the $143bn global cancer drug market, providing biopharma with the ability to query this real de-identified patient data to help create more targeted drug pipelines, reducing costly development cycles, unlocking new insights, and accessing real patient cohorts for clinical trial recruitment, bridging the gap between novel therapies and disease.